<< Boston Scientific reports two-year data from SYNTAX clinical trial | Reliable and relevant information needed to rein in the costs of federal health-care programs, says study >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski

Biodelivery Sciences International to participate in investor conferences

Published on September 3, 2009 at 8:17 AM · No Comments

BioDelivery Sciences International, Inc. (Nasdaq: BDSI) today announced its participation in the following upcoming investor conferences:

  • Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences, will present at the Robert W. Baird 2009 Health Care Conference on Wednesday, September 9, 2009 at 2:45 p.m. Eastern Time in New York City.
  • Dr. Sirgo will also present at the Rodman & Renshaw Annual Global Investment Conference on Thursday, September 10, 2009 at 2:00 p.m. Eastern Time in New York City.
  • Dr. Andrew L. Finn, BDSI’s Executive Vice President of Product Development, will present at the NewsMakers in the Biotech Industry Conference on Wednesday, September 16, 2009 at 11:00 a.m. Eastern Time in New York City.

Dr. Sirgo and Dr. Finn will be discussing the recent FDA approval and market opportunity for ONSOLIS (fentanyl buccal soluble film) and the status of BDSI’s product pipeline, including BEMA Buprenorphine and Bioral Amphotericin B.

http://www.biodeliverysciences.com

Posted in:

Tags: , , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading